Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.61 |
| ▸ | ADRB3 | P13945 | 9/20 | 0.53 |
| ▸ | ADRB2 | P07550 | 6/20 | 0.53 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.53 |
| ▸ | LTA4H | P09960 | 3/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | DRD1 | P21728 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10922516 | 1.00 | LMNA (0.67) | LMNASLC6A2PTGS1ADRB3ADRB2 | |
| SCHEMBL20272973 | 0.94 | LMNA (0.60) | LMNASLC6A2PTGS1ADRB3ADRB2 | |
| SCHEMBL5949941 | 0.91 | LMNA (0.78) | LMNASLC6A2PTGS1ADRB3ADRB2 | |
| SCHEMBL14441062 | 0.91 | LMNA (0.56) | LMNASLC6A2PTGS1ADRB3ADRB2 | |
| SCHEMBL15703195 | 0.91 | ESR1 (0.57) | LMNASLC6A2PTGS1ADRB3ADRB2 | |
| SCHEMBL823191 | 0.88 | HIF1A (0.55) | LMNASLC6A2PTGS1ADRB3ADRB2 | |
| SCHEMBL13892365 | 0.88 | HIF1A (0.55) | LMNASLC6A2PTGS1ADRB3ADRB2 | |
| SCHEMBL3173896 | 0.84 | SLC6A2 (0.58) | LMNASLC6A2PTGS1ADRB3ADRB2 | |
| SCHEMBL14570065 | 0.83 | LMNA (0.67) | LMNASLC6A2PTGS1MEN1CYP1A2 | |
| SCHEMBL28631164 | 0.83 | LMNA (0.67) | LMNALTA4HADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4539840-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | Neuron23, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119730846-A | Kinase modulators and methods of use thereof | 神经元23公司 | 2025-03-28 | — | — | CN | disclosed |
| WO-2023244788-A9 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2024-09-12 | — | — | WO | disclosed |
| US-20240025906-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | SUNDANCE BIOSCIENCES, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025906-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | SUNDANCE BIOSCIENCES, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025906-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | SUNDANCE BIOSCIENCES, INC. | 2024-01-25 | — | — | US | disclosed |
| WO-2023244788-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025906-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | TYK2, JAK1, JAK3 | LMNA 4294/4885SLC6A2 4424/4885PTGS1 1754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.